Below are the most recent publications written about "National Cancer Institute (U.S.)" by people in Profiles.
-
Burus T, McAfee CR, Hull PC, Leader AE, McNair C. Tracking community outreach and engagement activities among National Cancer Institute-designated cancer centers. J Natl Cancer Inst. 2025 Feb 01; 117(2):335-337.
-
Thompson HS, Ashing KT, Barrett NJ, Baskin ML, Carter-Bawa L, Nolan TS, Odedina FT, Rhoads KF, Sheppard VB, Zeigler-Johnson C. The state of cancer-focused community outreach and engagement (COE): reflections of Black COE directors. J Natl Cancer Inst. 2024 10 01; 116(10):1549-1554.
-
Ashare RL, Worster B, Nugent SM, Smith DM, Morasco BJ, Leader AE, Case AA, Meghani SH. Cannabis and opioid perceptions, co-use, and substitution among patients across 4 NCI-Designated Cancer Centers. J Natl Cancer Inst Monogr. 2024 08 15; 2024(66):267-274.
-
Ellison GL, Helzlsouer KJ, Rosenfield SM, Kim Y, Ashare RL, Blaes AH, Cullen J, Doran N, Ebbert JO, Egan KM, Heffner JL, Lee RT, McClure EA, McDaniels-Davidson C, Meghani SH, Newcomb PA, Nugent S, Hernandez-Ortega N, Salz T, Vidot DC, Worster B, Zylla DM. Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers. J Natl Cancer Inst Monogr. 2024 08 15; 2024(66):202-217.
-
Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 04; 8:e2300454.
-
Johnson SB, King AJ, Warner EL, Aneja S, Kann BH, Bylund CL. Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. JNCI Cancer Spectr. 2023 03 01; 7(2).
-
Hohl SD, Matulewicz RS, Salloum RG, Ostroff JS, Baker TB, Schnoll R, Warren G, Bernstein SL, Minion M, Lenhoff K, Dahl N, Juon HS, Tsosie U, Fleisher L, D'Angelo H, Ramsey AT, Ashing KT, Rolland B, Nolan MB, Bird JE, Nguyen CVT, Pauk D, Adsit RT, Tindle HA, Shoenbill K, Yeung S, Presant CA, Wiseman KP, Wen KY, Chichester LA, Chen LS. Integrating Tobacco Treatment Into Oncology Care: Reach and Effectiveness of Evidence-Based Tobacco Treatment Across National Cancer Institute-Designated Cancer Centers. J Clin Oncol. 2023 05 20; 41(15):2756-2766.
-
Lerman C, Hughes-Halbert C, Falcone M, Gosky DM, Jensen RA, Lee KP, Mitchell E, Odunsi K, Pegher JW, Rodriguez E, Sanchez Y, Shaw R, Weiner G, Willman CL. Leadership Diversity and Development in the Nation's Cancer Centers. J Natl Cancer Inst. 2022 09 09; 114(9):1214-1221.
-
Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. JCO Precis Oncol. 2022 07; 6:e2200165.
-
Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 02; 6:e2100424.